Glycotope Gmbh

Glycotype Gmbh

Nemod Biotherapeutics Gmbh & Co. Kg

Octapharma Ag

Te Bios Co., Ltd

Guangzhou Canton Biologics Co., Ltd.

Steffen Goletz

Antje Danielczyk

Uwe Karsten

Renate Stahn

Hans Baumeister

Lars Stöckl

Doreen Weigelt

Peter Ravn

Peter Astrup Christensen

Philippe Ulsemer

Ute Schöber

Anja Löffler

Rik J Scheper

Alan Masterson

Herbert M Pinedo

Marion Schlangstedt

Lars Stoeckl

Anja Loeffler

Ute Schoeber

Kawe Toutounian

Helmut Troester

Phillippe Ulsemer

Doreen Jahn

Rainer Stahn

Steffen Kreye

Sven Bahrke

Janine Guendel

Karina Nawrath

Anja LÖFFLER

Jana Vogt

The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.

Use of human cells of myeloid leukemia origin for expression of antibodies

The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.

Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters

The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.

Recognition molecules for the treatment and detection of tumors

The present invention pertains to microorganisms of the speciesexpressing a core-1 antigen on their surface. These microorganisms are in particular useful for the prophylaxis and treatment of core-1 positive diseases and are particularly characterized by a stable, homogenous high core-1 expression. Also provided are pharmaceutical compositions which comprise respective core-1 positive microorganisms or fractions thereof.

Microorganisms carrying a tumor antigen

The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment.

Recombinant human follicle-stimulating hormone

The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the same and to a method of prevention and treatment of core-1 positive disorders using the same. The invention relates to microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates.

Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates

The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to generate an immune response in humans. The invention further relates to methods for producing medicaments and diagnostic agents. Also disclosed is the use of the MUC1 molecules, cells or cell lysates obtained by means of the methods according to the invention for producing a medicament used for treating or preventing tumors. Further disclosed is a purified MUC1 molecule that can be obtained by means of the methods according to the invention and has an immunostimulating effect on humans. The invention additionally relates to the use of a MUC1 antibody for the production of a medicament used for treating or preventing tumors.

Method for the production of an immunostimulating mucin (MUC1)

The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life.

Fab-glycosylated antibodies

The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.

Tumor-specific recognition molecules

The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.

MUC1 antibodies

The present invention pertains to humanized anti-EGFR antibodies having antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. In particular, the present invention is directed to humanized anti-EGFR antibodies which are useful in the treatment of cancer.

Humanized EGFR antibodies

Use of human cells of myeloid leukaemia origin for expression of antibodies

The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and test systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.

MUTZ-3 dendritic cells

The present invention relates to a process for the purification of a glycoprotein comprising subjecting a liquid containing said glycoprotein to the steps of: a) reverse phase chromatography, b) size exclusion chromatography, and c) hydrophobic interaction chromatography. Also provided is a manufacturing process for producing a glycoprotein of interest.

Process for the purification of glycoproteins

The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising such recognition molecules, methods for the production of such recognition molecules, and to the use of such recognition molecules in the diagnosis and therapy of tumor diseases.

Growing community of inventors

Glienicke-Nordbahn, Germany

Steffen Goletz